Altimmune Inc (ALT)
7.09
-0.48
(-6.34%)
USD |
NASDAQ |
Apr 24, 16:00
7.06
-0.03
(-0.42%)
After-Hours: 17:05
Altimmune Enterprise Value: 338.86M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 338.86M |
| April 22, 2024 | 331.77M |
| April 19, 2024 | 292.07M |
| April 18, 2024 | 290.65M |
| April 17, 2024 | 301.29M |
| April 16, 2024 | 335.32M |
| April 15, 2024 | 337.44M |
| April 12, 2024 | 368.64M |
| April 11, 2024 | 397.71M |
| April 10, 2024 | 370.06M |
| April 09, 2024 | 397.71M |
| April 08, 2024 | 412.59M |
| April 05, 2024 | 446.62M |
| April 04, 2024 | 433.15M |
| April 03, 2024 | 460.80M |
| April 02, 2024 | 465.41M |
| April 01, 2024 | 527.44M |
| March 28, 2024 | 523.90M |
| March 27, 2024 | 432.44M |
| March 26, 2024 | 415.43M |
| March 25, 2024 | 406.92M |
| March 22, 2024 | 445.91M |
| March 21, 2024 | 446.06M |
| March 20, 2024 | 462.31M |
| March 19, 2024 | 419.91M |
| Date | Value |
|---|---|
| March 18, 2024 | 443.94M |
| March 15, 2024 | 499.06M |
| March 14, 2024 | 510.73M |
| March 13, 2024 | 573.28M |
| March 12, 2024 | 570.45M |
| March 11, 2024 | 499.77M |
| March 08, 2024 | 536.52M |
| March 07, 2024 | 511.08M |
| March 06, 2024 | 607.20M |
| March 05, 2024 | 596.60M |
| March 04, 2024 | 583.17M |
| March 01, 2024 | 656.67M |
| February 29, 2024 | 657.38M |
| February 28, 2024 | 740.78M |
| February 27, 2024 | 778.24M |
| February 26, 2024 | 602.25M |
| February 23, 2024 | 452.42M |
| February 22, 2024 | 429.09M |
| February 21, 2024 | 383.15M |
| February 20, 2024 | 395.88M |
| February 16, 2024 | 421.32M |
| February 15, 2024 | 434.75M |
| February 14, 2024 | 438.99M |
| February 13, 2024 | 400.12M |
| February 12, 2024 | 537.23M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-33.51M
Minimum
Aug 25 2023
984.81M
Maximum
Jul 20 2020
209.16M
Average
163.64M
Median
Oct 28 2020
Enterprise Value Benchmarks
| Eli Lilly and Co | 731.37B |
| Amgen Inc | 200.26B |
| Viking Therapeutics Inc | 6.163B |
| Precision BioSciences Inc | -22.76M |
| Terns Pharmaceuticals Inc | 39.78M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.64M |
| Revenue (Quarterly) | 0.037M |
| Total Expenses (Quarterly) | 21.24M |
| EPS Diluted (Quarterly) | -0.56 |
| Profit Margin (Quarterly) | -85.52K% |
| Earnings Yield | -23.55% |
| Normalized Earnings Yield | -23.55 |